Effect of continuous slow renal replacement therapies in the treatment of acute kidney injury in critically ill patients.

Effect of continuous slow renal replacement therapies in the treatment of acute kidney injury in critically ill patients. - ECO-LRA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

RPCEC

Registry ID

RPCEC00000476

Enrollment

240

Registered

2026-05-08

Start date

2026-05-29

Completion date

Unknown

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute kidney injury in critically ill patients.

Interventions

Group 1 (Experimental): Continuous slow renal replacement therapy (24 hours a day, 7 days a week) using the Prismaflex system will be used until renal function recovers and dialysis is no longer requi

Dialysis

Continuous Renal Replacement Therapy

Prismaflex System

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients over 18 years of age 2. Acute kidney injury defined by AKIN criteria 2-3 3. Severe hyperkalemia refractory to conventional treatment. 4. Severe metabolic acidosis refractory to medical treatment. 5. Fluid overload with pulmonary edema refractory to diuretics. 6. Poisoning by dialyzable drugs or toxins.

Exclusion criteria

Exclusion criteria: 1. Chronic kidney disease, presence of at least 2 previous plasma creatinine levels greater than 3 mg/dl (265 µmol/L) for more than 3 months or current dialysis treatment. 2. Patients with kidney transplantation. 3. Refusal of the patient or their family members or legal representative to participate in the study.

Design outcomes

Primary

Measure	Time frame
1. 28-day mortality (Proportion of patients who died within 28 days of starting renal replacement therapy). Measurement time: 28 days 2. Recovery of renal function (Proportion of patients who recover their urine output within 24 hours, normalize serum creatinine, and do not require dialysis therapy). Measurement time: At hospital discharge.	—

Secondary

Measure	Time frame
1. PO2/FiO2 ratio (Ratio of arterial oxygen pressure to inspired oxygen fraction). Measurement time: At baseline and, on days 3, 7, 14 and 28. 2. Need for mechanical ventilation (Yes, No). Measurement time: At baseline and, on days 3, 7, 14 and 28. 3. Need for vasopressor support (Yes, No). Measurement time: At baseline and, on days 3, 7, 14 and 28. 4. Inflammatory mediators (Values of Procalcitonin, Interleukin 6, C-reactive protein). Measurement time: At baseline and, on days 3, 7, 14 and 28. 5. Clinical laboratory tests (Values of Creatinine, Urea, pH, Serum potassium, Bicarbonate, Hemoglobin, and Hematocrit). Measurement time: Daily until at hospital discharge.	—

Measure

Time frame

1. PO2/FiO2 ratio (Ratio of arterial oxygen pressure to inspired oxygen fraction). Measurement time: At baseline and, on days 3, 7, 14 and 28. 2. Need for mechanical ventilation (Yes, No). Measurement time: At baseline and, on days 3, 7, 14 and 28. 3. Need for vasopressor support (Yes, No). Measurement time: At baseline and, on days 3, 7, 14 and 28. 4. Inflammatory mediators (Values of Procalcitonin, Interleukin 6, C-reactive protein). Measurement time: At baseline and, on days 3, 7, 14 and 28. 5. Clinical laboratory tests (Values of Creatinine, Urea, pH, Serum potassium, Bicarbonate, Hemoglobin, and Hematocrit). Measurement time: Daily until at hospital discharge.

—

Countries

Cuba

Contacts

Public ContactLeanet Quiles Gomez

Center for Medical-Surgical Research (CIMEQ)

emihf@infomed.sld.cu

Outcome results

None listed

Source: RPCEC (via WHO ICTRP) · Data processed: Aug 25, 2026